Genmab’s New Ofatumumab, Daratumumab Data Expected By Year End
This article was originally published in The Pink Sheet Daily
Executive Summary
Genmab has made progress with partnered lead antibodies ofatumumab and daratumumab in frontline CLL and refractory multiple myeloma respectively, while also boosting its financial guidance and cash balance.